Last updated: August 5, 2026
Technescan HDP is a mature technetium Tc 99m diagnostic radiopharmaceutical kit containing oxidronate sodium, also known as hydroxymethylene diphosphonate or HDP. It is used primarily for bone scintigraphy after reconstitution and labeling with technetium-99m. The product has no meaningful remaining innovator exclusivity, and its commercial outlook is driven more by radiopharmacy supply, hospital purchasing, isotope availability, and imaging volumes than by patent protection. Standalone revenue is not publicly disclosed.
What is Technescan HDP used for?
Technescan HDP is a prescription diagnostic kit for preparing technetium Tc 99m oxidronate injection. The labeled product accumulates in areas of increased osteogenic activity and is used for skeletal imaging, including evaluation of suspected bone metastases, fractures, infection, and other bone disorders.[1]
Product profile
| Attribute |
Technescan HDP |
| Active component |
Oxidronate sodium, also called HDP |
| Radiolabeled product |
Technetium Tc 99m oxidronate |
| Dosage form |
Nonradioactive lyophilized kit for injection |
| Administration |
Intravenous after reconstitution and radiolabeling |
| Primary use |
Bone scintigraphy |
| Therapeutic category |
Diagnostic radiopharmaceutical |
| Commercial sponsor |
Curium and related regional operating entities |
| Revenue disclosure |
Not separately reported |
| Main substitutes |
Tc 99m MDP, Tc 99m DPD and other bone-imaging agents |
| Main commercial constraint |
Reliable access to Tc 99m and Mo-99 supply |
The kit itself does not contain technetium-99m at the time of shipment. Radiopharmacies or nuclear medicine departments add sodium pertechnetate Tc 99m generated from a molybdenum-99/Tc 99m generator or obtained through an alternative supply chain.
How large is the Technescan HDP market?
The market is a mature segment of the broader nuclear medicine and bone-imaging market. Technescan HDP is not normally reported as a standalone product category in public industry revenue data.
Demand is tied to:
- The installed base of nuclear medicine cameras.
- Bone scan volumes in hospitals and outpatient imaging centers.
- The availability of Tc 99m generators and centralized radiopharmacy services.
- Reimbursement for nuclear medicine procedures.
- Physician substitution between HDP, MDP and other bone-seeking agents.
- The shift of some oncology and orthopedic imaging toward PET, CT, MRI and whole-body imaging.
Technescan HDP competes in a relatively stable but low-growth product segment. The product’s commercial value is based on recurring procedure demand and operational reliability rather than premium pricing or clinical differentiation.
Market-growth drivers
The main positive drivers are continued use of bone scintigraphy in oncology, trauma and infection imaging, particularly where PET or MRI is unavailable, unsuitable or more expensive. Tc 99m remains widely used because of its favorable physical properties, established supply chain and broad installed infrastructure.[2]
A second driver is the continued use of SPECT and SPECT/CT in hospitals with existing nuclear medicine capacity. Technescan HDP can be incorporated into routine radiopharmacy workflows without new imaging hardware.
Market constraints
The principal constraints are substitution and supply-chain exposure. Fluorine-18 sodium fluoride PET can provide high-quality skeletal imaging, while MRI and CT are preferred for many localized orthopedic indications. PET utilization remains limited by equipment access, reimbursement, isotope logistics and regional infrastructure.
Technescan HDP also depends on the broader Tc 99m supply chain. Reactor outages, generator constraints, transportation delays and shortages of molybdenum-99 can reduce procedure capacity even when demand for bone scans remains intact.[3]
What is the financial trajectory for Technescan HDP?
Technescan HDP is likely a stable-to-declining mature product rather than a high-growth pharmaceutical asset. Curium is privately held and does not report product-level sales, operating margins or cash-flow data for Technescan HDP. Public financial statements do not provide a separate revenue line that permits a reliable standalone valuation.
Financial characteristics
| Financial factor |
Expected effect |
| Product maturity |
Limits volume growth and pricing power |
| Patent position |
Provides no meaningful premium protection |
| Hospital contracts |
Supports recurring demand but pressures price |
| Tc 99m availability |
Creates volume volatility |
| Manufacturing scale |
Can support margin preservation |
| Radiopharmacy distribution |
Raises logistics and quality-control costs |
| Generic or alternative kits |
Limits price expansion |
| PET and MRI substitution |
Creates long-term volume pressure |
| Clinical standardization |
Supports continued baseline use |
| Product discontinuation risk |
Depends on supply economics and portfolio priorities |
Revenue performance is likely to track procedure volumes, market share and supply continuity. Price increases may be constrained because purchasers can often compare competing bone-agent kits and because the clinical use case is established rather than differentiated.
Financial trajectory by period
| Period |
Commercial outlook |
| Near term |
Stable demand with periodic volatility from isotope and logistics conditions |
| Medium term |
Low-single-digit pressure from substitution, contracting and mature procedure volumes |
| Long term |
Gradual erosion risk as PET, MRI and newer targeted imaging methods expand |
| Upside case |
Sustained Tc 99m availability, stable bone-scan utilization and production efficiency |
| Downside case |
Persistent isotope shortages, reimbursement pressure or accelerated migration to PET and MRI |
The product can remain economically useful even with declining unit volumes because diagnostic radiopharmaceuticals have repeat demand and relatively short inventory cycles. The key margin variables are manufacturing yield, batch release, distribution density, wastage and the cost of radiopharmacy operations.
What is the FDA regulatory status of Technescan HDP?
Technescan HDP is an FDA-approved diagnostic radiopharmaceutical kit. The FDA-approved labeling identifies the product as a kit for preparation of technetium Tc 99m oxidronate injection.[1]
Regulatory characteristics
The product is regulated as a prescription drug and diagnostic radiopharmaceutical. Its commercial use requires compliance with drug manufacturing controls, radiopharmacy handling requirements and applicable radioactive-material regulations.
The finished preparation has a short usable life because technetium-99m has a physical half-life of approximately six hours. That short half-life reduces conventional inventory risk but increases dependence on scheduled production, rapid distribution and same-day or near-term procedure utilization.
Technescan HDP does not have the regulatory profile of a biologic. Biosimilar competition is therefore not relevant. Competition occurs through alternative small-molecule radiopharmaceutical kits, compounded or repackaged products where permitted, and different imaging modalities.
What is the Orange Book status of Technescan HDP?
Technescan HDP is a mature product with no commercially important remaining new-drug exclusivity. The product’s principal commercial protection does not come from an active patent estate.
The FDA Orange Book is the relevant source for listed patents and regulatory exclusivity associated with approved drug products.[4] For an older diagnostic kit such as Technescan HDP, any original composition, formulation or use patents would generally have expired long before the current market period. The product’s current competitive position is therefore based on manufacturing authorization, quality systems, supply reliability, customer relationships and distribution rather than Orange Book exclusivity.
Exclusivity timeline
| Exclusivity category |
Current commercial significance |
| Original small-molecule composition protection |
Expired |
| Original formulation protection |
Expired or commercially immaterial |
| New chemical entity exclusivity |
Expired |
| Pediatric exclusivity |
No material relevance identified |
| Orphan-drug exclusivity |
Not applicable to the general bone-imaging indication |
| Orange Book patent barrier |
No meaningful current barrier expected |
| Biosimilar exclusivity |
Not applicable |
No credible commercial analysis should assign a patent-based price premium to Technescan HDP.
What patents protect Technescan HDP?
The relevant patent estate is effectively historical rather than active. Technescan HDP contains oxidronate, a long-established bisphosphonate used as a bone-seeking imaging ligand. The product is not protected by a modern composition-of-matter patent comparable to those covering newer oncology drugs or biologics.
Formulation and method-of-use protection
Potential historical protection could have covered:
- The oxidronate compound.
- Pharmaceutical formulations.
- Kit preparation and radiolabeling procedures.
- Use of the technetium-labeled compound for skeletal imaging.
Those categories do not create a meaningful present-day barrier. The product has been marketed for decades, and its approved use is established. Any residual manufacturing know-how is more relevant than patent exclusivity.
Manufacturing and intellectual-property barriers
The strongest barriers are operational:
- Validated sterile manufacturing.
- Control of radiochemical purity and labeling performance.
- Batch-release testing.
- Reliable access to pharmaceutical-grade oxidronate and kit components.
- Radiopharmacy distribution.
- Compliance with radioactive-material transport requirements.
- Capacity to coordinate production with Tc 99m availability.
These barriers can limit the number of reliable suppliers even when the underlying chemistry is old. They are not equivalent to patent exclusivity and generally support market participation rather than sustained monopoly pricing.
Are there Paragraph IV challenges to Technescan HDP?
Paragraph IV litigation is unlikely to be a material issue for Technescan HDP. Paragraph IV challenges arise when an abbreviated new drug application applicant certifies that a listed patent is invalid, unenforceable or will not be infringed. A mature diagnostic kit with no meaningful active Orange Book patent barrier does not present the typical litigation profile of a branded oral drug approaching loss of exclusivity.[4]
The principal competitive risk is commercial substitution or alternative approval, not a patent-driven generic launch event.
Generic entry risk
Generic-entry risk should be assessed through three channels:
| Risk channel |
Assessment |
| Patent-based entry |
Low significance because original exclusivity is exhausted |
| Regulatory entry |
Possible, subject to product-specific FDA requirements |
| Commercial entry |
Constrained by radiopharmaceutical manufacturing and distribution economics |
An entrant would need to demonstrate pharmaceutical quality, kit performance, radiochemical labeling characteristics and product consistency. Market access would also depend on securing hospital, radiopharmacy and distributor contracts.
Which companies compete with Technescan HDP?
Competition is fragmented across products and imaging modalities.
Direct product competition
The closest direct competitors are other technetium-labeled bone-agent kits, particularly:
- Technetium Tc 99m medronate, commonly known as MDP.
- Technetium Tc 99m oxidronate products from other suppliers.
- Technetium Tc 99m pyrophosphate in selected clinical contexts.
- Technetium Tc 99m dicarboxypropane diphosphonate, or DPD, in markets where available.
The competitive set varies by country because product approvals, hospital formularies, radiopharmacy practices and reimbursement rules differ.
Modality competition
Technescan HDP also competes indirectly with:
- Fluorine-18 sodium fluoride PET.
- FDG PET/CT for selected oncologic indications.
- Whole-body MRI.
- Diagnostic CT.
- Conventional MRI for localized musculoskeletal disease.
These modalities may offer superior sensitivity or anatomical detail in particular indications. They do not eliminate the need for bone scintigraphy across all settings because equipment availability, cost and clinical workflow differ.
How does Technescan HDP compare with Tc 99m MDP?
Technescan HDP and Tc 99m MDP are both established Tc 99m bone-imaging agents. The choice often reflects local procurement, historical physician practice, kit availability, radiopharmacy workflow and reimbursement rather than a decisive patent or clinical differentiation.
| Comparison |
Technescan HDP |
Tc 99m MDP |
| Active ligand |
Oxidronate |
Medronate |
| Imaging use |
Bone scintigraphy |
Bone scintigraphy |
| Technology |
Tc 99m-labeled kit |
Tc 99m-labeled kit |
| Market maturity |
Mature |
Mature |
| Patent-driven differentiation |
Minimal |
Minimal |
| Supply-chain exposure |
Mo-99/Tc 99m dependent |
Mo-99/Tc 99m dependent |
| Substitution risk |
High within bone-agent class |
High within bone-agent class |
| Commercial differentiator |
Supply reliability and contracts |
Supply reliability and contracts |
The practical commercial contest is often between suppliers and radiopharmacy networks rather than between patented molecules.
What litigation and settlement agreements affect Technescan HDP?
No major current patent litigation or settlement agreement is central to Technescan HDP’s market position. The product’s commercial risk is operational and competitive.
Relevant legal exposure is more likely to involve:
- Product quality or manufacturing compliance.
- Radioactive-material transport.
- Supply agreements.
- Hospital purchasing contracts.
- Distribution arrangements.
- Regulatory compliance.
- Product liability.
There is no apparent litigation-driven launch calendar comparable to branded drugs with active Orange Book patents and multiple Paragraph IV filers.
What licensing deals support Technescan HDP?
No major publicly disclosed licensing transaction appears to determine Technescan HDP’s current economics. The product is part of Curium’s broader nuclear medicine portfolio, which includes diagnostic radiopharmaceuticals, isotope supply capabilities and radiopharmacy infrastructure.[5]
Portfolio-level arrangements can affect product economics through:
- Manufacturing rights.
- Regional commercialization rights.
- Distributor access.
- Generator and isotope supply.
- Hospital network contracts.
- Technology transfer.
- Contract manufacturing.
Because the product is mature and not separately reported, a standalone licensing valuation would not be supportable from public disclosures.
What geographic markets are relevant to Technescan HDP?
Technescan HDP is most commercially relevant in markets with established nuclear medicine infrastructure and dependable Tc 99m supply.
Geographic factors
In the United States, market access depends on FDA approval, radiopharmacy distribution and hospital purchasing. In Europe and other regions, national marketing authorizations, local suppliers, reimbursement and isotope logistics determine availability.
Geographic performance can diverge because:
- Tc 99m generator penetration varies.
- Reactor and processor supply chains differ.
- PET and MRI access is uneven.
- Radiopharmacy consolidation differs by country.
- Product names and suppliers may change across jurisdictions.
- Local compounding rules affect substitution.
A supplier with broad regional manufacturing and distribution can outperform a technically equivalent competitor during isotope shortages or transportation disruptions.
What generic launch scenarios exist for Technescan HDP?
The most likely launch scenario is incremental competition from an equivalent or near-equivalent radiopharmaceutical kit, rather than a single high-impact patent expiry.
Scenario analysis
| Scenario |
Market effect |
| Stable incumbent supply |
Gradual price and volume pressure |
| New reliable kit supplier |
Share loss through hospital and radiopharmacy tenders |
| Tc 99m shortage |
Temporary volume disruption for all suppliers |
| PET substitution |
Long-term decline in selected bone-scan indications |
| Manufacturing interruption |
Rapid customer switching and potential supply premiums |
| Hospital consolidation |
Greater buyer leverage and lower prices |
| Reimbursement reduction |
Lower procedure volumes and contracting pressure |
Technescan HDP is vulnerable to share loss if a competitor offers equivalent performance with more reliable delivery. It is less vulnerable to a classic sudden generic cliff because the original product is already mature and the market has multiple substitution pathways.
How strong is the Technescan HDP patent estate?
The patent estate is weak as a current commercial asset. Its effective strength is near zero for purposes of blocking generic or alternative kit competition.
The defensible value lies in:
- Product registration.
- Manufacturing validation.
- Quality documentation.
- Radiopharmacy relationships.
- Distribution capacity.
- Isotope procurement.
- Operational consistency.
Those assets can support recurring cash flow but do not justify a patent-based terminal value or exclusivity premium.
Key Takeaways
- Technescan HDP is a mature Tc 99m oxidronate bone-imaging kit.
- Its market is driven by bone-scintigraphy volumes, radiopharmacy infrastructure and Tc 99m availability.
- Curium does not publicly report standalone Technescan HDP revenue.
- Original patent and regulatory exclusivity have no meaningful current commercial effect.
- Paragraph IV litigation and biosimilar risk are not material competitive issues.
- The closest competitors are Tc 99m MDP, other Tc 99m bone-agent kits and alternative imaging modalities.
- Financial performance is likely stable to gradually declining, with periodic supply-driven volatility.
- Manufacturing, isotope procurement and distribution are stronger barriers than patents.
- The principal long-term risks are PET, MRI and CT substitution, hospital purchasing pressure and radiopharmaceutical supply disruptions.
- The product’s value is operational and portfolio-based, not patent-based.
FAQs
Does Technescan HDP contain radioactive technetium when shipped?
No. It is supplied as a nonradioactive kit. Technetium-99m is added before administration through a radiopharmacy or nuclear medicine workflow.
Is Technescan HDP interchangeable with Tc 99m MDP?
They are competing bone-imaging agents, but interchangeability depends on local product approvals, labeling, institutional protocols and radiopharmacy practices.
Does Technescan HDP have biosimilar competition?
No. Technescan HDP is a small-molecule radiopharmaceutical kit, not a biologic. Its competition comes from equivalent or alternative radiopharmaceuticals and imaging modalities.
What is the main supply risk for Technescan HDP?
The main risk is disruption in the Mo-99/Tc 99m supply chain, followed by manufacturing, quality-release and time-sensitive distribution constraints.
Can Technescan HDP support premium pricing?
Sustained patent-based premium pricing is unlikely. Temporary premiums may arise from supply shortages, superior delivery reliability or limited regional competition.
References
- U.S. Food and Drug Administration. (n.d.). Technescan HDP: Prescribing information. FDA.
- Society of Nuclear Medicine and Molecular Imaging. (n.d.). Bone scintigraphy and radiopharmaceutical practice resources. SNMMI.
- Organisation for Economic Co-operation and Development Nuclear Energy Agency. (2023). The supply of medical radioisotopes: 2023 medical radioisotopes supply review. OECD Publishing.
- U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. FDA.
- Curium Pharma. (n.d.). Technescan HDP and nuclear medicine products. Curium Pharma.
